摘要
目的探讨慢性心力衰竭患者进行β受体阻滞剂治疗的临床效果及安全性。方法入选我院2014年5月至2015年1月收治的慢性心力衰竭患者90例,随机分为两组各45例。对照组仅进行一般疗法,实验组在此基础上给予依那普利与酒石酸美托洛尔治疗,比较两组的临床效果、心功能指标、心律及心率情况。结果实验组的临床总有效率为88.9%,显著高于对照组的66.7%,差异有统计学意义(P<0.05);实验组治疗后的射血分数(EF)、左室收缩末内径(LY-ESD)、左室舒张末内径(LVEDD)、心脏指数(CI)、心排血量(CO)等心功能指标显著优于对照组,差异有统计学意义(P<0.05);实验组治疗后的室性早搏个数、房性早搏个数显著优于对照组,差异有统计学意义(P<0.05);实验组治疗后心率略有减低,但与对照组比较,差异无统计学意义(P>0.05)。结论慢性心力衰竭患者进行β受体阻滞剂治疗,可显著改善患者的心功能状态,临床效果确切,但需从小剂量逐渐加量,老年患者对其耐受性稍差。
Objective To explore the clinical effect and safety of β receptor blocker for the treatment of chronic heart failure （CHF） patients. Methods Ninety cases of CHF patients admitted to our hospital from May 2014 to January 2015 were selected and randomly divided into two groups, with 45 cases in each group. The control group was given with routine therapy, while the experimental group was given enalapril combined with metoprolol tartrate on the basis of routine therapy. The clinical effect, heart function indexes, and the rhythm and rate of heart were compared between two groups. Results The total effective rate of experimental group was 88.9%, significantly higher than 66.7% of control group （P 〈0.05）. The heart function indices including ejection fraction （EF）, left ventficular end-systolic diameter （LY-ESD）, left ventricular end-diastolic diameter （LVEDD）, cardiac index （CI）, cardiac output （CO） of the experimental group were better than those of the control group （P〈0.05）. The number of premature ventricular excitation and the number of premature atrium excitation of the experimental group were significantly better than those of the control group （P〈0.05）. No statistical difference was found between two groups in the heart rate after therapy （P〉0.05）. Conclusions For CHF patients,β receptor blocker can significantly improve patients＇ cardiac functions and has obvious clinical effects. However, the dosage should be gradually increased, and elderly patients have a poorer tolerance.
出处
《临床医学工程》
2015年第5期562-564,共3页
Clinical Medicine & Engineering
基金
梅州市科技计划项目(项目编号:2014B146)
关键词
临床研究
耐受性
慢性心力衰竭
Β受体阻滞剂
Clinical research
Tolerance
Chronic heart failure （CHF）
β receptor blocker
